Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases - Tập 19 - Trang 1013-1022 - 2019
Kayvon Modjarrad1, Christine C Roberts2, Kristin T Mills3, Amy R Castellano4, Kristopher Paolino1, Kar Muthumani5, Emma L Reuschel5, Merlin L Robb4, Trina Racine6, Myoung-don Oh7, Claude Lamarre6, Faraz I Zaidi5, Jean Boyer8, Sagar B Kudchodkar2, Moonsup Jeong2, Janice M Darden9, Young K Park2, Paul T Scott1, Celine Remigio2, Ajay P Parikh4
1Walter Reed Army Institute for Research, Silver Spring, MD, USA
2GeneOne Life Science, Seoul, South Korea
3ICON Clinical Research Management, Gaithersburg, MD, USA
4Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
5Wistar Institute, Philadelphia, PA, USA
6Université Laval, Quebec City, QC, Canada
7Seoul National University College of Medicine, Seoul, South Korea
8Inovio Pharmaceuticals, Plymouth Meeting, PA, USA
9Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Infectious Diseases

Tập 19

1013-1022

Thông tin tác giả